Morningstar

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

MELBOURNE, Australia, July 2, 2025 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative ...
Hosted on MSN

Neurizon’s ALS expansion data supports NUZ-001 advancement to HEALEY trial

Neurizon Therapeutics’ disease-modifying drug NUZ-001 has been shown to be safe and effective over 2.5 years of dosing in patients with amyotrophic lateral sclerosis (ALS), further setting it up for ...
Hosted on MSN

FDA Clears Path for Neurizon’s ALS Drug NUZ-001 in Pivotal Trial

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Pharmaust Limited ( ...
Morningstar

NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease

NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease Treatment prevented hallmark developmental and ...